organization · Reporting owner

Temasek Holdings (Private) Ltd

Disclosed activity across 20 companies

Tapewire entity: 11958
SEC CIK: 0001021944

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Coherus Oncology, Inc.CHRS · Entity 6276	10% owner	December 30, 2019	January 08, 2020
Flywire CorpFLYW · Entity 1568	10% owner	May 28, 2021	June 01, 2021
Intapp, Inc.INTA · Entity 352	10% owner	November 17, 2023	November 20, 2023
Pear Therapeutics, Inc.PEAR · Entity 114512	10% owner	December 03, 2021	December 10, 2021
SQZ Biotechnologies CoSQZ · Entity 112267	10% owner	November 03, 2020	November 05, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Coherus Oncology, Inc.

Report date December 30, 2019 · Filed January 08, 2020

Jointly reported with V-Sciences Investments Pte Ltd, Temasek Life Sciences Private Ltd, Fullerton Management Pte Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,381,116	Reported balance Holding disclosure · report date 2019-12-30 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 7,381,116 F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

Filing footnotes · ownership attribution and instrument terms

F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

Flywire Corp

Report date May 28, 2021 · Filed June 01, 2021

Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Fullerton Management Pte Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2021-05-28 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2021-05-28 · Conversion · Acquired 9,514,293 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 3 · 2021-05-28 · Other · Disposed 10,635,573 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2021-05-28 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2021-05-28 · Conversion · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 5 · 2021-05-28 · Other · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Voting common stockSEC Table I · non-derivative	Direct	10,635,573	Reported balance After 2021-05-28 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-05-28 · Other · Acquired 10,635,573 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Non-voting common stockSEC Table I · non-derivative	Direct	1,873,320	Reported balance After 2021-05-28 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2021-05-28 · Other · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series A preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-28 · Conversion · Disposed 97,173 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series B preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-28 · Conversion · Disposed 2,100,129 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series C preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-28 · Conversion · Disposed 547,008 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series D preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-28 · Conversion · Disposed 6,625,002 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series E-2 preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-28 · Conversion · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series F preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-05-28 · Conversion · Disposed 144,981 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7.

F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Intapp, Inc.

Report date November 17, 2023 · Filed November 20, 2023

Jointly reported with Anderson Investments Pte. Ltd., Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	IndirectSee footnote	17,146,805	Reported balance After 2023-11-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-11-17 · Sale · Disposed 2,500,000 · Balance 17,146,805 F1: 15,226,805 shares are held of record by Anderson Investments Pte. Ltd. ("Anderson Investments"), which is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson Capital"). Thomson Capital is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu Capital"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Thomson Capital and Tembusu Capital may therefore be deemed to have or share beneficial ownership of the securities held by Anderson Investments. 1,920,000 shares are held of record by another indirect wholly-owned subsidiary of Temasek Holdings, which may therefore, through the direct and indirect ownership described above, be deemed to have or share beneficial ownership of the aggregate of the securities beneficially owned by Tembusu Capital and the aforesaid other indirect wholly-owned subsidiary of Temasek Holdings.

Filing footnotes · ownership attribution and instrument terms

F1: 15,226,805 shares are held of record by Anderson Investments Pte. Ltd. ("Anderson Investments"), which is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson Capital"). Thomson Capital is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu Capital"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Thomson Capital and Tembusu Capital may therefore be deemed to have or share beneficial ownership of the securities held by Anderson Investments. 1,920,000 shares are held of record by another indirect wholly-owned subsidiary of Temasek Holdings, which may therefore, through the direct and indirect ownership described above, be deemed to have or share beneficial ownership of the aggregate of the securities beneficially owned by Tembusu Capital and the aforesaid other indirect wholly-owned subsidiary of Temasek Holdings.

Pear Therapeutics, Inc.

Report date December 03, 2021 · Filed December 10, 2021

Jointly reported with TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Fullerton Management Pte Ltd, Elbrus Investments Pte. Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnotes	26,803,573	Reported balance Holding disclosure · report date 2021-12-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 26,803,573 F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd. F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.

F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SQZ Biotechnologies Co

Report date November 03, 2020 · Filed November 05, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee note	1,888,924	Reported balance After 2020-11-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-11-03 · Conversion · Acquired 1,888,924 · Balance 1,888,924 F1: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held of record by Elbrus Investments Pte. Ltd. ("Elbrus"). Elbrus is a direct wholly owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a direct wholly owned subsidiary of Fullerton Management Pte Ltd, which in turn is a direct wholly owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the shares held of record by Elbrus.
Common StockSEC Table I · non-derivative	IndirectSee note	2,513,924	Reported balance After 2020-11-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-11-03 · Purchase · Acquired 625,000 · Balance 2,513,924 F3: The shares are held of record by V-Sciences Investments Pte Ltd. ("V-Sciences"). V-Sciences is a direct wholly owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a direct wholly owned subsidiary of Fullerton Management Pte Ltd, which in turn is a direct wholly owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the shares held of record by V-Sciences.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2020-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-03 · Conversion · Disposed 1,888,924 · Balance 0 F1: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held of record by Elbrus Investments Pte. Ltd. ("Elbrus"). Elbrus is a direct wholly owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a direct wholly owned subsidiary of Fullerton Management Pte Ltd, which in turn is a direct wholly owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the shares held of record by Elbrus.

Filing footnotes · ownership attribution and instrument terms

F1: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2: The shares are held of record by Elbrus Investments Pte. Ltd. ("Elbrus"). Elbrus is a direct wholly owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a direct wholly owned subsidiary of Fullerton Management Pte Ltd, which in turn is a direct wholly owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the shares held of record by Elbrus.

F3: The shares are held of record by V-Sciences Investments Pte Ltd. ("V-Sciences"). V-Sciences is a direct wholly owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a direct wholly owned subsidiary of Fullerton Management Pte Ltd, which in turn is a direct wholly owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the shares held of record by V-Sciences.

Past disclosures · reporting ended (15)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMYRIS, INC.

Report date May 07, 2018 · Filed May 09, 2018

Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Fullerton Management Pte Ltd

Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,207,423	Reported balance After 2018-05-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-07 · Sale · Disposed 95,162 · Balance 3,207,423 F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd.

Akili, Inc.

Report date July 02, 2024 · Filed July 05, 2024

Jointly reported with TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Fullerton Management Pte Ltd

Section 16 reporting ended · disclosed 2024-07-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2024-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-07-02 · Other · Disposed 10,336,425 · Balance 0 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.
Earnout SharesSEC Table II · derivative / convertible security · Expires 2027-08-19	IndirectSee Footnote	0	Reported balance After 2024-07-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-07-02 · Other · Disposed 1,172,697 · Balance 0 F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price.

F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.

F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement.

Blend Labs, Inc.

Report date July 20, 2021 · Filed July 22, 2021

Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Fullerton Management Pte Ltd

Section 16 reporting ended · disclosed 2021-07-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	11,875,773	Reported balance After 2021-07-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series E convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-20 · Conversion · Disposed 10,949,867 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series F convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-20 · Conversion · Disposed 925,906 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table II · derivative / convertible security	Direct	11,875,773	Reported balance After 2021-07-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-20 · Conversion · Disposed 11,875,773 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred.

F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date.

F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Dell Technologies Inc.

Report date August 30, 2019 · Filed September 04, 2019

Section 16 reporting ended · disclosed 2019-09-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class C Common StockSEC Table I · non-derivative	IndirectSee footnotes	17,579,064	Reported balance After 2019-08-30 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-08-30 · Sale · Disposed 602,754 · Balance 17,579,064 F1: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F2: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.9975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) and (7) to this Form 4. F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Class C Common StockSEC Table I · non-derivative	IndirectSee footnotes	16,691,440	Reported balance After 2019-08-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-08-30 · Sale · Disposed 887,624 · Balance 16,691,440 F1: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F3: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.98, inclusive. F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Class C Common StockSEC Table I · non-derivative	IndirectSee footnotes	15,980,867	Reported balance After 2019-08-30 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2019-08-30 · Sale · Disposed 710,573 · Balance 15,980,867 F1: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F4: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $52.03 to $52.90, inclusive. F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Class C Common StockSEC Table I · non-derivative	IndirectSee footnotes	15,956,268	Reported balance After 2019-08-30 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2019-08-30 · Sale · Disposed 24,599 · Balance 15,956,268 F1: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F5: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $53.00 to $53.16, inclusive. F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Class C Common StockSEC Table I · non-derivative	IndirectSee footnotes	15,513,516	Reported balance After 2019-09-03 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-09-03 · Sale · Disposed 442,752 · Balance 15,513,516 F6: On September 3, 2019, Venezio Investments Pte. Ltd. sold 442,752 shares of Common Stock. F7: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.87, inclusive. F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16.

F2: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.9975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) and (7) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.98, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $52.03 to $52.90, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $53.00 to $53.16, inclusive.

F6: On September 3, 2019, Venezio Investments Pte. Ltd. sold 442,752 shares of Common Stock.

F7: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.87, inclusive.

F8: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

FTS International, Inc.

Report date August 26, 2021 · Filed August 31, 2021

Jointly reported with Maju Investments (Mauritius) Pte Ltd, Fullerton Fund Investments Pte Ltd

Section 16 reporting ended · disclosed 2021-08-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.04 · Expires 2023-11-19	IndirectSee footnote	54,713	Reported balance After 2021-08-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-26 · Sale · Disposed 534,000 · Balance 54,713 F1: Maju Investments (Mauritius) Pte Ltd is wholly owned by Fullerton Fund Investments Pte Ltd, which is wholly owned by Temasek Holdings (Private) Limited. Accordingly, Fullerton Fund Investments Pte Ltd and Temasek Holdings (Private) Limited may be deemed to be indirect beneficial owners of the Class A Common Stock beneficially owned directly by Maju Investments (Mauritius) Pte Ltd.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.14 · Expires 2023-11-19	IndirectSee footnote	937,783	Reported balance After 2021-08-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-26 · Sale · Disposed 534,000 · Balance 937,783 F1: Maju Investments (Mauritius) Pte Ltd is wholly owned by Fullerton Fund Investments Pte Ltd, which is wholly owned by Temasek Holdings (Private) Limited. Accordingly, Fullerton Fund Investments Pte Ltd and Temasek Holdings (Private) Limited may be deemed to be indirect beneficial owners of the Class A Common Stock beneficially owned directly by Maju Investments (Mauritius) Pte Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: Maju Investments (Mauritius) Pte Ltd is wholly owned by Fullerton Fund Investments Pte Ltd, which is wholly owned by Temasek Holdings (Private) Limited. Accordingly, Fullerton Fund Investments Pte Ltd and Temasek Holdings (Private) Limited may be deemed to be indirect beneficial owners of the Class A Common Stock beneficially owned directly by Maju Investments (Mauritius) Pte Ltd.

Guardant Health, Inc.

Report date October 09, 2018 · Filed October 11, 2018

Jointly reported with TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Fullerton Management Pte Ltd

Section 16 reporting ended · disclosed 2018-10-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	IndirectBy TLS Beta Pte. Ltd.	1,016,995	Reported balance After 2018-10-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-10-09 · Conversion · Acquired 1,016,995 · Balance 1,016,995 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
COMMON STOCKSEC Table I · non-derivative	IndirectBy TLS Beta Pte. Ltd.	596,012	Reported balance After 2018-10-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-10-09 · Conversion · Acquired 596,012 · Balance 596,012 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
SERIES D PREFERRED STOCKSEC Table II · derivative / convertible security	IndirectBy TLS Beta Pte. Ltd.	0	Reported balance After 2018-10-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-10-09 · Conversion · Disposed 1,016,995 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
SERIES E PREFERRED STOCKSEC Table II · derivative / convertible security	IndirectBy TLS Beta Pte. Ltd.	0	Reported balance After 2018-10-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-10-09 · Conversion · Disposed 596,012 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

LEVEL 3 COMMUNICATIONS INC

Report date November 01, 2017 · Filed November 03, 2017

Jointly reported with STT Crossing Ltd, STT Communications Ltd, Singapore Technologies Telemedia Pte Ltd

Section 16 reporting ended · disclosed 2017-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-11-01 · Other · Disposed 65,031,667 · Balance 0 F1: Disposition pursuant to the acquisition of the issuer, Level 3 Communications, Inc. ("Level 3"), by CenturyLink, Inc. ("CenturyLink") pursuant to an agreement and plan of merger, dated as of October 31, 2016 (the "Merger Agreement"), by and among Level 3, CenturyLink and two indirect wholly owned subsidiaries of CenturyLink. Pursuant to the Merger Agreement, each share of Level 3 common stock was converted into the right to receive $26.50 in cash and 1.4286 shares of CenturyLink common stock. F2: Temasek Holdings (Private) Limited ("Temasek") is the parent of Singapore Technologies Telemedia Pte Ltd, which is the direct parent of STT Communications Ltd, which is the parent of STT Crossing Ltd ("STT Crossing"), the designated filer. Because of the foregoing relationships, the direct and indirect parents of STT Crossing may be deemed to indirectly own the reported securities directly owned by STT Crossing. Temasek disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Disposition pursuant to the acquisition of the issuer, Level 3 Communications, Inc. ("Level 3"), by CenturyLink, Inc. ("CenturyLink") pursuant to an agreement and plan of merger, dated as of October 31, 2016 (the "Merger Agreement"), by and among Level 3, CenturyLink and two indirect wholly owned subsidiaries of CenturyLink. Pursuant to the Merger Agreement, each share of Level 3 common stock was converted into the right to receive $26.50 in cash and 1.4286 shares of CenturyLink common stock.

F2: Temasek Holdings (Private) Limited ("Temasek") is the parent of Singapore Technologies Telemedia Pte Ltd, which is the direct parent of STT Communications Ltd, which is the parent of STT Crossing Ltd ("STT Crossing"), the designated filer. Because of the foregoing relationships, the direct and indirect parents of STT Crossing may be deemed to indirectly own the reported securities directly owned by STT Crossing. Temasek disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Lumen Technologies, Inc.

Report date January 16, 2019 · Filed January 18, 2019

Section 16 reporting ended · disclosed 2019-01-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $1.00 per shareSEC Table I · non-derivative	IndirectSee Footnote	107,201,207	Reported balance After 2019-01-16 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-01-16 · Sale · Disposed 16,000,000 · Balance 107,201,207 F1: As of January 17, 2019, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of January 17, 2019, Aranda Investments Pte. Ltd. ("Aranda") directly owns 30,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of January 17, 2019, Temasek Holdings may be deemed to beneficially own the 107,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital.

Filing footnotes · ownership attribution and instrument terms

F1: As of January 17, 2019, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of January 17, 2019, Aranda Investments Pte. Ltd. ("Aranda") directly owns 30,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of January 17, 2019, Temasek Holdings may be deemed to beneficially own the 107,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital.

PORTOLA PHARMACEUTICALS INC

Report date June 01, 2017 · Filed June 05, 2017

Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Fullerton Management Pte Ltd

Section 16 reporting ended · disclosed 2017-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	4,133,568	Reported balance After 2017-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-06-01 · Sale · Disposed 1,700,000 · Balance 4,133,568 F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively.

Filing footnotes · ownership attribution and instrument terms

F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively.

Poshmark, Inc.

Report date May 25, 2022 · Filed May 27, 2022

Jointly reported with Tembusu Capital Pte. Ltd., Thomson Capital Pte. Ltd., Anderson Investments Pte. Ltd.

Section 16 reporting ended · disclosed 2022-05-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	IndirectSee Footnote	3,971,646	Reported balance After 2022-05-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-05-25 · Sale · Disposed 2,000,000 · Balance 3,971,646 F1: Anderson Investments Pte. Ltd ("Anderson") is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson"), which in turn is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Accordingly, Thomson, Tembusu and Temasek may be deemed to beneficially own the shares of Class A common stock directly owned by Anderson.

Filing footnotes · ownership attribution and instrument terms

F1: Anderson Investments Pte. Ltd ("Anderson") is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson"), which in turn is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Accordingly, Thomson, Tembusu and Temasek may be deemed to beneficially own the shares of Class A common stock directly owned by Anderson.

Q32 Bio Inc.

Report date April 02, 2018 · Filed April 04, 2018

Jointly reported with Fullerton Management Pte Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd

Section 16 reporting ended · disclosed 2018-04-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,605,681	Reported balance After 2018-04-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-04-02 · Conversion · Acquired 1,605,681 · Balance 1,605,681 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,595,293	Reported balance After 2018-04-02 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-04-02 · Conversion · Acquired 989,612 · Balance 2,595,293 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,220,293	Reported balance After 2018-04-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-04-02 · Purchase · Acquired 625,000 · Balance 3,220,293 F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2018-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-04-02 · Conversion · Disposed 1,605,681 · Balance 0 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2018-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-04-02 · Conversion · Disposed 989,612 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.

F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta.

F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.

SES AI Corp

Report date September 19, 2024 · Filed September 23, 2024

Jointly reported with Temasek Capital (Private) Ltd, Thomson Capital Pte. Ltd., Anderson Investments Pte. Ltd., Tembusu Capital Pte. Ltd., Seletar Investments Pte Ltd, Aranda Investments Pte. Ltd.

Section 16 reporting ended · disclosed 2024-09-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy Fund	2,550,901	Reported balance After 2024-09-19 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2024-09-19 · Sale · Disposed 467,143 · Balance 2,550,901 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.9386 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held by Aranda Investments Pte. Ltd. ("Aranda"). Aranda is a direct wholly-owned subsidiary of Seletar Investments Pte. Ltd. ("Seletar"), which in turn is a direct wholly-owned subsidiary of Temasek Capital (Private) Limited ("Capital"), which in turn is a direct wholly-owned subsidiary of Temasek. In such capacities, each of Seletar, Capital, and Temasek may be deemed to have voting and dispositive power over the shares held by Aranda. Each of Seletar, Capital and Temasek disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Fund	2,297,782	Reported balance After 2024-09-20 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2024-09-20 · Sale · Disposed 253,119 · Balance 2,297,782 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7712 to $0.8605 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held by Aranda Investments Pte. Ltd. ("Aranda"). Aranda is a direct wholly-owned subsidiary of Seletar Investments Pte. Ltd. ("Seletar"), which in turn is a direct wholly-owned subsidiary of Temasek Capital (Private) Limited ("Capital"), which in turn is a direct wholly-owned subsidiary of Temasek. In such capacities, each of Seletar, Capital, and Temasek may be deemed to have voting and dispositive power over the shares held by Aranda. Each of Seletar, Capital and Temasek disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Fund	25,882,916	Reported balance Holding disclosure · report date 2024-09-19 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 25,882,916 F4: These shares are held by Anderson Investments Pte. Ltd ("Anderson"). Anderson is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson"), which in turn is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). In such capacities, each of Thomson, Tembusu, and Temasek may be deemed to have voting and dispositive power over the shares held by Anderson. Each of Thomson, Tembusu and Temasek disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.9386 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: These shares are held by Aranda Investments Pte. Ltd. ("Aranda"). Aranda is a direct wholly-owned subsidiary of Seletar Investments Pte. Ltd. ("Seletar"), which in turn is a direct wholly-owned subsidiary of Temasek Capital (Private) Limited ("Capital"), which in turn is a direct wholly-owned subsidiary of Temasek. In such capacities, each of Seletar, Capital, and Temasek may be deemed to have voting and dispositive power over the shares held by Aranda. Each of Seletar, Capital and Temasek disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7712 to $0.8605 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These shares are held by Anderson Investments Pte. Ltd ("Anderson"). Anderson is a direct wholly-owned subsidiary of Thomson Capital Pte. Ltd. ("Thomson"), which in turn is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd. ("Tembusu"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). In such capacities, each of Thomson, Tembusu, and Temasek may be deemed to have voting and dispositive power over the shares held by Anderson. Each of Thomson, Tembusu and Temasek disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.

Univar Solutions Inc.

Report date January 31, 2018 · Filed February 07, 2018 · Amendment

Jointly reported with Dahlia Investments Pte. Ltd., Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd.

Section 16 reporting ended · disclosed 2018-02-07. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	14,078,012	Reported balance After 2018-01-31 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2018-01-31 · Other · Disposed 3,952 · Balance 14,078,012 F1: The Reporting Person's board nominee, Juliet Teo, resigned on January 31, 2018. The Reporting Person is therefore no longer entitled to the 3,952 shares of restricted stock that would have vested in full on May 3, 2018, if such Reporting Person's board nominee had remained on the board through such date. F2: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person's board nominee, Juliet Teo, resigned on January 31, 2018. The Reporting Person is therefore no longer entitled to the 3,952 shares of restricted stock that would have vested in full on May 3, 2018, if such Reporting Person's board nominee had remained on the board through such date.

F2: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd.

Vir Biotechnology, Inc.

Report date October 16, 2019 · Filed October 18, 2019

Jointly reported with Fullerton Management Pte Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd

Section 16 reporting ended · disclosed 2019-10-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,333,333	Reported balance After 2019-10-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-10-16 · Conversion · Acquired 3,333,333 · Balance 3,333,333 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,999,999	Reported balance After 2019-10-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2019-10-16 · Conversion · Acquired 1,666,666 · Balance 4,999,999 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,499,999	Reported balance After 2019-10-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2019-10-16 · Purchase · Acquired 500,000 · Balance 5,499,999 F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2019-10-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-16 · Conversion · Disposed 3,333,333 · Balance 0 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2019-10-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-16 · Conversion · Disposed 1,666,666 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date.

F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta.

F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta.

F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Virtu Financial, Inc.

Report date May 13, 2020 · Filed May 15, 2020

Section 16 reporting ended · disclosed 2020-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stock, par value $0.00001 per shareSEC Table I · non-derivative	IndirectSee note	11,380,503	Reported balance After 2020-05-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-05-13 · Sale · Disposed 5,500,000 · Balance 11,380,503 F1: Havelock Fund Investments Pte Ltd ("Havelock") directly owns 8,867,682 Class A common stock, par value $0.00001 per share ("Class A Shares"). Havelock is wholly owned by Fullerton Fund Investments Pte. Ltd. ("Fullerton"). Fullerton may be deemed to beneficially own the Class A Shares beneficially owned by Havelock. Aranda Investments Pte. Ltd. ("Aranda") directly owns 2,512,821 Class A Shares. Aranda is wholly owned by Seletar Investments Pte. Ltd. ("Seletar"), which is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Each of Seletar and Temasek Capital may be deemed to beneficially own the Class A Shares beneficially owned by Aranda. Each of Temasek Capital and Fullerton are wholly owned by Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the 11,380,503 Class A Shares deemed to be beneficially owned in the aggregate by Temasek Capital and Fullerton.

Filing footnotes · ownership attribution and instrument terms

F1: Havelock Fund Investments Pte Ltd ("Havelock") directly owns 8,867,682 Class A common stock, par value $0.00001 per share ("Class A Shares"). Havelock is wholly owned by Fullerton Fund Investments Pte. Ltd. ("Fullerton"). Fullerton may be deemed to beneficially own the Class A Shares beneficially owned by Havelock. Aranda Investments Pte. Ltd. ("Aranda") directly owns 2,512,821 Class A Shares. Aranda is wholly owned by Seletar Investments Pte. Ltd. ("Seletar"), which is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Each of Seletar and Temasek Capital may be deemed to beneficially own the Class A Shares beneficially owned by Aranda. Each of Temasek Capital and Fullerton are wholly owned by Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the 11,380,503 Class A Shares deemed to be beneficially owned in the aggregate by Temasek Capital and Fullerton.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 16, 2019 Filed Oct 18, 2019 20:16 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	ConversionSeries A-1 Preferred Stock · Derivative	3,333,333	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025766 · doc4.xml · derivative · entry 4 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,333,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · shares: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · ownership.nature: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
October 16, 2019 Filed Oct 18, 2019 20:16 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	PurchaseCommon Stock	500,000	$20.00	$10,000,000.00	Disclosure SEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 3 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,499,999 F5 · ownership.nature: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
October 16, 2019 Filed Oct 18, 2019 20:16 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	ConversionCommon Stock	1,666,666	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,999,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4 · ownership.nature: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
October 16, 2019 Filed Oct 18, 2019 20:16 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	ConversionCommon Stock	3,333,333	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,333,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F3 · ownership.nature: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
September 03, 2019 Filed Sep 4, 2019 15:54 UTC	Dell Technologies Inc. DELL · Entity 2822	SaleClass C Common Stock	442,752	$51.22	$22,677,270.41	Disclosure SEC source: 0001387131-19-006672 · dell-form4_083019.xml · nonDerivative · entry 5 Temasek Holdings (Private) Ltd · CIK 0001021944 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 15,513,516 F6 · kind: On September 3, 2019, Venezio Investments Pte. Ltd. sold 442,752 shares of Common Stock. F7 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.87, inclusive. F6 · ownership.nature: On September 3, 2019, Venezio Investments Pte. Ltd. sold 442,752 shares of Common Stock. F8 · ownership.nature: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
August 30, 2019 Filed Sep 4, 2019 15:54 UTC	Dell Technologies Inc. DELL · Entity 2822	SaleClass C Common Stock	24,599	$53.02	$1,304,243.90	Disclosure SEC source: 0001387131-19-006672 · dell-form4_083019.xml · nonDerivative · entry 4 Temasek Holdings (Private) Ltd · CIK 0001021944 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 15,956,268 F1 · kind: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F5 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $53.00 to $53.16, inclusive. F1 · ownership.nature: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F8 · ownership.nature: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
August 30, 2019 Filed Sep 4, 2019 15:54 UTC	Dell Technologies Inc. DELL · Entity 2822	SaleClass C Common Stock	710,573	$52.20	$37,091,555.31	Disclosure SEC source: 0001387131-19-006672 · dell-form4_083019.xml · nonDerivative · entry 3 Temasek Holdings (Private) Ltd · CIK 0001021944 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 15,980,867 F1 · kind: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F4 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $52.03 to $52.90, inclusive. F1 · ownership.nature: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F8 · ownership.nature: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
August 30, 2019 Filed Sep 4, 2019 15:54 UTC	Dell Technologies Inc. DELL · Entity 2822	SaleClass C Common Stock	887,624	$51.41	$45,632,572.32	Disclosure SEC source: 0001387131-19-006672 · dell-form4_083019.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 16,691,440 F1 · kind: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F3 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $51.00 to $51.98, inclusive. F1 · ownership.nature: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F8 · ownership.nature: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
August 30, 2019 Filed Sep 4, 2019 15:54 UTC	Dell Technologies Inc. DELL · Entity 2822	SaleClass C Common Stock	602,754	$50.50	$30,436,183.78	Disclosure SEC source: 0001387131-19-006672 · dell-form4_083019.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 17,579,064 F1 · kind: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.9975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) and (7) to this Form 4. F1 · ownership.nature: On August 30, 2019, Venezio Investments Pte. Ltd. sold an aggregate of 2,225,550 shares of Class C common stock, par value $0.01 per share (the "Common Stock"), of Dell Technologies Inc. (the "Issuer") in multiple transactions at prices ranging from $50.00 to $53.16. F8 · ownership.nature: The Common Stock is directly held by Venezio Investments Pte. Ltd., which is a direct wholly-owned subsidiary of Napier Investments Pte. Ltd. Napier Investments Pte. Ltd. is a direct wholly-owned subsidiary of Tembusu Capital Pte. Ltd., which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Napier Investments Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by Venezio Investments Pte. Ltd. Each such person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
January 16, 2019 Filed Jan 18, 2019 11:05 UTC	Lumen Technologies, Inc. CTL · Entity 3749	SaleCommon Stock, par value $1.00 per share	16,000,000	$15.90	$254,400,000.00	Disclosure SEC source: 0000899243-19-001453 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 107,201,207 F1 · balance_after: As of January 17, 2019, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of January 17, 2019, Aranda Investments Pte. Ltd. ("Aranda") directly owns 30,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of January 17, 2019, Temasek Holdings may be deemed to beneficially own the 107,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.direct: As of January 17, 2019, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of January 17, 2019, Aranda Investments Pte. Ltd. ("Aranda") directly owns 30,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of January 17, 2019, Temasek Holdings may be deemed to beneficially own the 107,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.nature: As of January 17, 2019, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of January 17, 2019, Aranda Investments Pte. Ltd. ("Aranda") directly owns 30,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of January 17, 2019, Temasek Holdings may be deemed to beneficially own the 107,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. Read SEC document
October 09, 2018 Filed Oct 11, 2018 20:29 UTC	Guardant Health, Inc. GH · Entity 3238	ConversionSERIES E PREFERRED STOCK · Derivative	596,012	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 4 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 0 Underlying: COMMON STOCK · 596,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document
October 09, 2018 Filed Oct 11, 2018 20:29 UTC	Guardant Health, Inc. GH · Entity 3238	ConversionSERIES D PREFERRED STOCK · Derivative	1,016,995	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 3 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 0 Underlying: COMMON STOCK · 1,016,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document
October 09, 2018 Filed Oct 11, 2018 20:29 UTC	Guardant Health, Inc. GH · Entity 3238	ConversionCOMMON STOCK	596,012	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 2 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 596,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document
October 09, 2018 Filed Oct 11, 2018 20:29 UTC	Guardant Health, Inc. GH · Entity 3238	ConversionCOMMON STOCK	1,016,995	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 1 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 1,016,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document
May 15, 2018 Filed May 15, 2018 20:11 UTC	Virtu Financial, Inc. VIRT · Entity 3811	SaleClass A Common Stock, par value $0.00001 per share	3,450,000	$27.16	$93,702,000.00	Disclosure SEC source: 0000947871-18-000418 · ss92303_4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 16,880,503 F1 · kind: This sale was made pursuant to a prospectus filed by Virtu Financial, Inc. (the "Issuer") with the Securities and Exchange Commission on May 11, 2018, in connection with the offering of an aggregate of 17,250,000 Class A Shares of the Issuer's common stock ("Class A Shares") (consisting of a base deal of 15,000,000 Class A Shares and an additional 2,250,000 Class A Shares sold pursuant to the underwriters' option to purchase additional shares). The shares sold were previously held by Havelock Fund Investments Pte Ltd ("Havelock") and sold in the offering on May 15, 2018 for cash consideration of $27.16 per share. F2 · ownership.nature: Havelock directly owns 8,867,682 Class A Shares. Havelock is wholly owned by Fullerton Fund Investments Pte. Ltd. ("FFI"). FFI may be deemed to beneficially own the shares beneficially owned by Havelock. Aranda Investments Pte. Ltd. ("Aranda") directly owns 8,012,821 shares of Issuer's Class A common stock. Aranda is wholly owned by Seletar Investments Pte. Ltd. ("Seletar"), which is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Each of Seletar and Temasek Capital may be deemed to beneficially own the 8,012,821 Class A Shares beneficially owned by Aranda. Each of Temasek Capital and FFI are wholly owned by Temasek Holdings (Private) Limited ("Temasek"). Therefore, Temasek may be deemed to beneficially own the 16,880,503 Class A Shares deemed to be beneficially owned in the aggregate by Temasek Capital and FFI. Read SEC document
May 07, 2018 Filed May 9, 2018 13:29 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	95,162	$6.54	$622,635.45	Disclosure SEC source: 0000899243-18-012036 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207,423 F1 · balance_after: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
April 05, 2018 Filed Apr 9, 2018 10:51 UTC	Lumen Technologies, Inc. CTL · Entity 3749	PurchaseCommon Stock, par value $1.00 per share	5,036,884	$17.41	$87,700,209.45	Disclosure SEC source: 0000899243-18-009709 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 123,201,207 F1 · balance_after: As of April 6, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 6, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 6, 2018, Temasek Holdings may be deemed to beneficially own the 123,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.direct: As of April 6, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 6, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 6, 2018, Temasek Holdings may be deemed to beneficially own the 123,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.nature: As of April 6, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 30,296,968 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 6, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 6, 2018, Temasek Holdings may be deemed to beneficially own the 123,201,207 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. Read SEC document
April 04, 2018 Filed Apr 5, 2018 16:04 UTC	Lumen Technologies, Inc. CTL · Entity 3749	PurchaseCommon Stock, par value $1.00 per share	4,308,851	$16.94	$72,977,285.85	Disclosure SEC source: 0000899243-18-009528 · doc4.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 118,164,323 F1 · balance_after: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.direct: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.nature: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. Read SEC document
April 03, 2018 Filed Apr 5, 2018 16:04 UTC	Lumen Technologies, Inc. CTL · Entity 3749	PurchaseCommon Stock, par value $1.00 per share	3,311,267	$16.43	$54,396,169.77	Disclosure SEC source: 0000899243-18-009528 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 113,855,472 F1 · balance_after: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.direct: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. F1 · ownership.nature: As of April 4, 2018, Everitt Investments Pte. Ltd. ("Everitt") and Ellington Investments Pte. Ltd. ("Ellington") directly own 46,452,120 and 25,260,084 shares of the Issuer's common stock ("Common Stock"), respectively. Everitt and Ellington are each wholly owned by Bartley Investments Pte. Ltd., which in turn is wholly owned by Tembusu Capital Pte. Ltd. ("Tembusu Capital"). As of April 4, 2018, Aranda Investments Pte. Ltd. ("Aranda") directly own 46,452,119 shares of Common Stock. Aranda is wholly owned by Seletar Investments Pte Ltd, which in turn is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Tembusu Capital and Temasek Capital are each wholly owned by Temasek Holdings (Private) Limited ("Temasek Holdings"). Therefore, as of April 4, 2018, Temasek Holdings may be deemed to beneficially own the 118,164,323 shares of Common Stock beneficially owned in aggregate by Tembusu Capital and Temasek Capital. Read SEC document
April 02, 2018 Filed Apr 4, 2018 17:33 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionSeries B Preferred Stock · Derivative	989,612	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 5 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 989,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · shares: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · ownership.nature: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document
April 02, 2018 Filed Apr 4, 2018 17:33 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionSeries A Preferred Stock · Derivative	1,605,681	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 4 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,605,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · shares: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · ownership.nature: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document
April 02, 2018 Filed Apr 4, 2018 17:33 UTC	Q32 Bio Inc. FIXX · Entity 5594	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 3 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,220,293 F5 · ownership.nature: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Read SEC document
April 02, 2018 Filed Apr 4, 2018 17:33 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionCommon Stock	989,612	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,595,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4 · ownership.nature: Consists of 989,612 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document
April 02, 2018 Filed Apr 4, 2018 17:33 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionCommon Stock	1,605,681	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,605,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F3 · ownership.nature: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document
January 31, 2018 Filed Feb 2, 2018 16:17 UTC	Univar Solutions Inc. UNVR · Entity 110826	OtherCommon Stock, par value $0.01 per share	3,952	$0.00	$0.00	Disclosure SEC source: 0000903423-18-000059 · temasek4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,078,012 F1 · shares: The Reporting Person's board nominee, Juliet Teo, resigned on January 31, 2018. The Reporting Person is therefore no longer entitled to the 3,952 shares of restricted stock that would have vested in full on May 3, 2018, if such Reporting Person's board nominee had remained on the board through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 31, 2018 Filed Feb 7, 2018 16:45 UTC Amendment	Univar Solutions Inc. UNVR · Entity 110826	OtherCommon Stock, par value $0.01 per share	3,952	$0.00	$0.00	Disclosure SEC source: 0000903423-18-000065 · temasek4a.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,078,012 F1 · shares: The Reporting Person's board nominee, Juliet Teo, resigned on January 31, 2018. The Reporting Person is therefore no longer entitled to the 3,952 shares of restricted stock that would have vested in full on May 3, 2018, if such Reporting Person's board nominee had remained on the board through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 25, 2018 Filed Jan 26, 2018 14:24 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	1,515	$31.25	$47,347.08	Disclosure SEC source: 0000903423-18-000041 · temasek4.xml · nonDerivative · entry 2 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,081,964 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 24, 2018 Filed Jan 26, 2018 14:24 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	4,120	$31.10	$128,145.60	Disclosure SEC source: 0000903423-18-000041 · temasek4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083,479 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 23, 2018 Filed Jan 24, 2018 14:44 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	800	$31.10	$24,881.04	Disclosure SEC source: 0000903423-18-000037 · temasek4.xml · nonDerivative · entry 2 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,087,599 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd Read SEC document
January 22, 2018 Filed Jan 24, 2018 14:44 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	9,550	$31.12	$297,232.29	Disclosure SEC source: 0000903423-18-000037 · temasek4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,088,399 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd Read SEC document
January 19, 2018 Filed Jan 23, 2018 02:38 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	1,700	$31.11	$52,892.78	Disclosure SEC source: 0001140361-18-002817 · form4.xml · nonDerivative · entry 2 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,097,949 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 18, 2018 Filed Jan 23, 2018 02:38 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	315	$31.18	$9,820.25	Disclosure SEC source: 0001140361-18-002817 · form4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · See Remarks Thomson Capital Pte. Ltd. · CIK 0001568354 · See Remarks Tembusu Capital Pte. Ltd. · CIK 0001512449 · See Remarks Temasek Holdings (Private) Ltd · CIK 0001021944 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,099,649 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the Reporting Person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 17, 2018 Filed Jan 18, 2018 15:07 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	45,000	$31.02	$1,396,030.50	Disclosure SEC source: 0000903423-18-000026 · temasek4.xml · nonDerivative · entry 2 Dahlia Investments Pte. Ltd. · CIK 0001568351 · 10% owner Thomson Capital Pte. Ltd. · CIK 0001568354 · 10% owner Tembusu Capital Pte. Ltd. · CIK 0001512449 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,099,964 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the reporting person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
January 16, 2018 Filed Jan 18, 2018 15:07 UTC	Univar Solutions Inc. UNVR · Entity 110826	SaleCommon Stock, par value $0.01 per share	30,587	$31.31	$957,654.50	Disclosure SEC source: 0000903423-18-000026 · temasek4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · 10% owner Thomson Capital Pte. Ltd. · CIK 0001568354 · 10% owner Tembusu Capital Pte. Ltd. · CIK 0001512449 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,144,964 F1 · balance_after: Inclusive of 3,952 shares of restricted stock that vests in full on May 3, 2018, subject to the continued board service of the reporting person's board nominee, Juliet Teo, through such date. F2 · ownership.direct: Dahlia Investments Pte. Ltd. directly owns the shares of the Issuer's Common Stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer's Common Stock that are directly owned by Dahlia Investments Pte. Ltd. Read SEC document
November 01, 2017 Filed Nov 3, 2017 08:15 UTC	LEVEL 3 COMMUNICATIONS INC LVLT · Entity 172141	OtherCommon Stock	65,031,667	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-025356 · doc4.xml · nonDerivative · entry 1 STT CROSSING LTD · CIK 0001271837 · 10% owner STT COMMUNICATIONS LTD · CIK 0001139158 · 10% owner SINGAPORE TECHNOLOGIES TELEMEDIA PTE LTD · CIK 0001219573 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition pursuant to the acquisition of the issuer, Level 3 Communications, Inc. ("Level 3"), by CenturyLink, Inc. ("CenturyLink") pursuant to an agreement and plan of merger, dated as of October 31, 2016 (the "Merger Agreement"), by and among Level 3, CenturyLink and two indirect wholly owned subsidiaries of CenturyLink. Pursuant to the Merger Agreement, each share of Level 3 common stock was converted into the right to receive $26.50 in cash and 1.4286 shares of CenturyLink common stock. F1 · price: Disposition pursuant to the acquisition of the issuer, Level 3 Communications, Inc. ("Level 3"), by CenturyLink, Inc. ("CenturyLink") pursuant to an agreement and plan of merger, dated as of October 31, 2016 (the "Merger Agreement"), by and among Level 3, CenturyLink and two indirect wholly owned subsidiaries of CenturyLink. Pursuant to the Merger Agreement, each share of Level 3 common stock was converted into the right to receive $26.50 in cash and 1.4286 shares of CenturyLink common stock. F2 · ownership.direct: Temasek Holdings (Private) Limited ("Temasek") is the parent of Singapore Technologies Telemedia Pte Ltd, which is the direct parent of STT Communications Ltd, which is the parent of STT Crossing Ltd ("STT Crossing"), the designated filer. Because of the foregoing relationships, the direct and indirect parents of STT Crossing may be deemed to indirectly own the reported securities directly owned by STT Crossing. Temasek disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
August 10, 2017 Filed Aug 11, 2017 15:50 UTC	Virtu Financial, Inc. VIRT · Entity 3811	PurchaseClass A Common Stock, par value $0.00001 per share	1,666,666	$15.60	$25,999,989.60	Disclosure SEC source: 0000947871-17-000638 · ss54933_4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,330,503 F1 · ownership.nature: Aranda Investments Pte. Ltd. ("Aranda") directly owns 8,012,821 shares of Issuer's Class A common stock. Aranda is wholly owned by Seletar Investments Pte. Ltd. ("Seletar"), which is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Each of Seletar and Temasek Capital may be deemed to beneficially own the 8,012,821 shares of Issuer's Class A common stock beneficially owned by Aranda. Havelock Fund Investments Pte. Ltd. ("Havelock") directly owns 12,317,682 shares of Issuer's Class A common stock. Havelock is wholly owned by Fullerton Fund Investments Pte. Ltd. ("FFI"). FFI may be deemed to beneficially own the shares beneficially owned by Havelock. Each of Temasek Capital and FFI are wholly owned by Temasek Holdings (Private) Ltd ("Temasek"). Therefore, Temasek may be deemed to beneficially own the 20,330,503 shares of Issuer's Class A common stock deemed to be beneficially owned in the aggregate by Temasek Capital and FFI. Read SEC document
July 20, 2017 Filed Jul 24, 2017 22:24 UTC	Virtu Financial, Inc. VIRT · Entity 3811	PurchaseClass A Common Stock, par value $0.00001 per share	6,346,155	$15.60	$99,000,018.00	Disclosure SEC source: 0000947871-17-000563 · ss52545_4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,663,837 F1 · ownership.nature: Aranda Investments Pte. Ltd. ("Aranda") directly owns 6,346,155 shares of Issuer's Class A common stock. Aranda is wholly owned by Seletar Investments Pte. Ltd. ("Seletar"), which is wholly owned by Temasek Capital (Private) Limited ("Temasek Capital"). Each of Seletar and Temasek Capital may be deemed to beneficially own the 6,346,155 shares of Issuer's Class A common stock beneficially owned by Aranda. Havelock Fund Investments Pte. Ltd. ("Havelock") directly owns 12,317,682 shares of Issuer's Class A common stock. Havelock is wholly owned by Fullerton Fund Investments Pte. Ltd. ("FFI"). FFI may be deemed to beneficially own the shares beneficially owned by Havelock. Each of Temasek Capital and FFI are wholly owned by Temasek Holdings (Private) Ltd ("Temasek"). Therefore, Temasek may be deemed to beneficially own the 18,663,837 shares of Issuer's Class A common stock deemed to be beneficially owned in the aggregate by Temasek Capital and FFI. Read SEC document
June 01, 2017 Filed Jun 5, 2017 12:01 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon stock	1,700,000	$34.40	$58,480,000.00	Disclosure SEC source: 0000899243-17-015234 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,133,568 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively. Read SEC document
May 05, 2017 Filed May 9, 2017 18:00 UTC	AMYRIS, INC. AMRS · Entity 91367	Other6.50% Convertible Senior Notes due 2019 (the "Notes") · Derivative	Not disclosed	$0.00 Strike: $3.74	$10,000,000.00	Disclosure SEC source: 0000899243-17-012448 · doc4.xml · derivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · kind: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · reported_value: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · price: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · derivative.exercise_date: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · derivative.expiration_date: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F2 · ownership.direct: Maxwell directly owns the Notes. Maxwell is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd., which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd. may be deemed to beneficially own the shares of derivative securities directly owned by Maxwell. Read SEC document
May 04, 2017 Filed May 10, 2017 13:33 UTC	Univar Solutions Inc. UNVR · Entity 110826	OtherCommon Stock, par value $0.01 per share	3,952	$0.00	$0.00	Disclosure SEC source: 0000903423-17-000315 · temasek4.xml · nonDerivative · entry 1 Dahlia Investments Pte. Ltd. · CIK 0001568351 · 10% owner Thomson Capital Pte. Ltd. · CIK 0001568354 · 10% owner Tembusu Capital Pte. Ltd. · CIK 0001512449 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,175,551 F1 · kind: Restricted stock that vests in full on May 3, 2018, subject to the continued board service of the reporting person's board nominee, Juliet Teo, through such date. F2 · ownership.nature: Dahlia Investments Pte. Ltd. beneficially owns 14,175,551 shares of Issuer's common stock. Dahlia Investments Pte. Ltd. is wholly owned by Thomson Capital Pte. Ltd., which is wholly-owned by Tembusu Capital Pte. Ltd., which is wholly-owned by Temasek Holdings (Private) Limited. Each of Thomson Capital Pte. Ltd., Tembusu Capital Pte. Ltd. and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares held by Dahlia Investments Pte. Ltd. Read SEC document
April 20, 2017 Filed Apr 21, 2017 10:05 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	313,649	$0.51	$160,839.21	Disclosure SEC source: 0000899243-17-010671 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,538,771 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 49,538,771 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
April 19, 2017 Filed Apr 21, 2017 10:05 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	338,864	$0.59	$198,438.76	Disclosure SEC source: 0000899243-17-010671 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,852,420 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 49,538,771 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
April 18, 2017 Filed Apr 19, 2017 13:09 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	699,705	$0.61	$425,000.82	Disclosure SEC source: 0000899243-17-010505 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,191,284 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 50,191,284 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
April 17, 2017 Filed Apr 19, 2017 13:09 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	937,225	$0.68	$640,218.40	Disclosure SEC source: 0000899243-17-010505 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,890,989 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 50,191,284 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 30, 2017 Filed Apr 3, 2017 10:11 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	184,535	$0.51	$94,481.92	Disclosure SEC source: 0000899243-17-009072 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,828,214 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 51,828,214 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 29, 2017 Filed Mar 30, 2017 12:21 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	300,470	$0.52	$155,643.46	Disclosure SEC source: 0000899243-17-008874 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,012,749 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,012,749 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 28, 2017 Filed Mar 30, 2017 12:21 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	117,520	$0.48	$56,914.94	Disclosure SEC source: 0000899243-17-008874 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,313,219 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,012,749 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 27, 2017 Filed Mar 28, 2017 11:00 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	86,613	$0.48	$41,920.69	Disclosure SEC source: 0000899243-17-008742 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,430,739 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,430,739 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 24, 2017 Filed Mar 28, 2017 11:00 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	42,446	$0.48	$20,543.86	Disclosure SEC source: 0000899243-17-008742 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,517,352 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,430,739 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
March 23, 2017 Filed Mar 24, 2017 10:44 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	43,482	$0.49	$21,110.51	Disclosure SEC source: 0000899243-17-008462 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,559,798 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,559,798 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.